Among the heterocyclic compounds, 8-aminoquinoline and its derivatives have become important candidates for the preparation of new antiproliferative metallo-drugs. Here, we reported the synthesis and cytotoxicity evaluation of a series of platinum complexes using 8aminoquinoline and its chiral 5,6,7,8-tetrahydro-derivatives as chelating ligands. In the proposed complexes, a differently and opportunely alkylated imidazole was used to prepare the corresponding monofunctional platinum complexes. The preliminary cytotoxicity evaluation was carried out on the highly aggressive MDA-MB-231, invasive and poorly differentiated triple-negative breast cancer (TNBC) cell line, furnishing a significant IC50 10.9±1.3 µM for Pt-IV. This series of complexes revealed an induction of p53, interfering with the progression of the G0/G1 phase of the cell cycle.
Introduction
8-aminoquinoline and its derivatives are heterocyclic compounds that are drawing attention in the field of coordination chemistry due to their metal-binding ability along with a variety of biological effects. [1] Known for their recognised antimalarial properties, 8aminoquinoline analogues such as sitamaquine and NPC1161 are currently investigated for their antileishmanial and antitrypanosomal activities. [2] More recently, an increasing number of 8-aminoquinoline related compounds have been investigated as anticancer agents for their ability to trigger different antiproliferative effects such as the inhibition of tyrosine kinases, tubulin polymerization, topoisomerase and DNA mechanisms of repair. [3] From a structural point of view, the presence of two nitrogen donor atoms make them bidentate chelating ligands able to form thermodynamically stable coordinative complexes with metal ions providing them with novel biochemical properties. [4] Thus, 8-aminoquinolines are beheld as a privileged framework for the preparation of new metallodrug candidates. A recent paper [5] reported the use of N- (quinoline-8-yl) quinolin-8-sulfonamide as ligand for the synthesis of a copper (II) complex endowed with intercalation properties and the ability to trigger DNA fragmentation and apoptosis in Jurkat T cells. [6] Additionally, a series of transition metal complexes of mixed ligands 8-aminoquine-5-substituted uracil bases have been investigated for their cytotoxicity showing a significant activity against MOLT-3 cancer cells. [7] Based on these premises and considering that the anticancer potential of platinum (II) 8-aminoquinolines complexes has been poorly explored, 8-aminoquinoline scaffold has been selected for the preparation of monofunctional platinum complexes. [8] This class of anticancer agents, bearing just one substitution-labile ligand, has recently emerged for their unconventional mechanisms of action compared to cisplatin-like drugs, their potent cytotoxic activity and their distinctive anticancer spectrum of action. Although there is a certain interaction with DNA double helix, cationic platinum complexes stood out for their ability to affect different cell targets becoming a potential tool for the treatment of aggressive and/or orphan cancers. Moreover, the cellular uptake of the cationic monofunctional platinum complexes by the organic cation transporters (OCTs) could provide an opportunity for a selective delivery to tumours known for overexpressing these channels, such as the human colorectal cancer. [9] Our research group have recently reported a series of cationic platinum complexes obtained by the addition of an alkylated imidazole ligand to the dichloride neutral precursor led to charged platinum compounds. This series showed a novel cytotoxic profile involving mechanisms of action not related to a simple DNA crosslinking as established for cisplatin. The so-synthesised cationic platinum compounds displayed a potent anticancer effect on different cancer cell lines known for their poor sensitivity to cisplatin chemotherapy. [10] In the present study, we reported the synthesis and cytotoxicity evaluation of a series of platinum complexes using 8-aminoquinoline and its chiral 5,6,7,8-tetrahydro-derivatives [11] as chelating ligands and in which different alkylated imidazoles were used to prepare the corresponding monofunctional platinum complexes.
In previous works, two different series of platinum compounds bearing N-alkyl aminomethyl-imidazole ligands were synthetized. Both the series, dichloride and cationic ones, were evaluated for their in vitro cytotoxic activity, with the cationic compounds having the best results in terms of cytotoxicity. [4a, 10a, 12] Considering the favourable introduction of a differently substituted alkyl-imidazole as additional monocoordinated ligand to form the monofunctional cationic platinum (II) complexes, the choice to conserve this moiety and instead to modify the bidentate ligands was applied, with the aim to verify the effect of the bidentate ligands on the biological activity. The synthesis of platinum compounds, bearing the commercially available 8-aminoquinoline L1 as ligand, proceeded as reported in Figure 1 . The complexes were fully characterized by 1 H-NMR, 195 Pt-NMR, elemental analysis and ESI-MS. With the aim to verify the correct conformation of the complexes, and considering that only one stereoisomer was formed during the synthesis, as evinced by NMR spectroscopy and by RP-HPLC, 2D-NMR experiment (NOESY) was performed for complex Pt-IV. (spectrum reported in SI) The presence of the only one cross-peak between the H in 2 position and H in 3 position on pyridine ring confirmed that the imidazole moiety was stereoselectively coordinated in trans to the nitrogen of pyridine as designed for all the complexes in the Figure 1 . Considering the possibility to selectively reduce the aromatic ring of the pyridine or the phenolic one, ligands L2, L3 and L4 were synthetized. In particular, the ligands L3 and L4, being respectively the S and R enantiomers of a tetrahydroquinoline, called CAMPY, were resolved and synthetized as previously reported. [11] (Figure 2 ) The corresponding platinum compounds Pt-VI-XI, were fully characterized as for Pt-I-IV and the chemical structures were again confirmed by NOESY experiments. The determination of log Pow was evaluated for all the platinum complexes by RP-HPLC, equipped with C18 ODS at 25 °C with water/methanol in ratio 80/20 in presence of HCOOH 15 mM as eluent, and using commercially available platinum complexes as references. [13] The values were generally comparable, in a range of 0.65-1.51, depending on the type of the aromaticity of the bidentate ligands and on the length of the alkyl chain on imidazole monodentate ligand. Figure 2 . Synthesis of Pt-V-XI. Reagents and Conditions: i) PtO2 10%, H2 (5 atm), CF3CCOH, 4h; ii) MsCl, DMAP, CH2Cl2, DMSO, 18 h; iii) Pd/C 5%, H2 (10 atm), MeOH, 4h; iv) K2PtCl4, H2O, reflux for 18 h; v) PtO2 5%, H2 (5 atm), CF3CCOH, 4h; vi) vinyl acetate, Cal. B Lipase, mol. sieves 4 Å , diisopropyl ether, 60°C, 30h; vii) K2CO3, MeOH, reflux, 2h; viii) Alkyl-imidazole, DMF, 55°C 18 h.
The cytotoxicity of platinum (II) complexes on triple negative breast cancer MDA-MB-231 cell line was tested in vitro by sulforhodamine B (SRB) assay. After 48 h incubation with increasing concentration of the compounds, the IC50 values were determined. As shown in Table 1 , all the complexes significantly reduced, by more than 50%, the cell viability with IC50 values ranging from 4.5±0.5 µM (Pt-I) [14] up to 195.8±27.9 µM (Pt-VII). Importantly, the cytotoxic effects of the most active compounds, were confirmed by MTT assay (Table  1) . Table 1 . Cytotoxic effects of tested platinum (II) complexes on MDA-MB-231.
Complex
LogP (RP-HPLC)
Cisplatin -2.21 [15] 59.4 ± 10.06 31.5 ± 4.9
Pt-I 1. 51 To extend this observation we investigated the cytotoxic effects of the most promising cationic pyridine complexes, such as Pt-IV, Pt-VIII and Pt-XI, on A2780 ovarian cell line. As reported in Table 1 , Pt-IV appeared to elicit a similar cytotoxic effect on both cell lines, while the two enantiomers Pt-VIII and Pt-XI show a more potent cytotoxic effect on A2780 compared to MDA-MB-231, as indicated by lower IC50 values. To investigate the molecular mechanism of the cytotoxic effect observed with Pt-IV, Pt-VIII and Pt-XI, we performed a cell cycle analysis and determined the expression levels of p53 and proliferating cell nuclear antigen (PCNA). Cisplatin was utilized as positive control. Pt-VIII and Pt-XI determined a significant accumulation of proliferating MDA-MB-231 cells into G0/G1 cell line with a concomitant reduction of G2/M. This effect is concentration dependent and appears to be different than cisplatin that slightly reduced the percentage of cells in G0/G1. By western blot analysis, we observed a drastic reduction of p53 and PCNA levels after incubation of the cells with 100 µM concentration of Pt-VIII and Pt-XI. Surprisingly, also the intracellular levels of housekeeping proteins, such as α-tubulin and β-actin, were significantly reduced in response to both compounds. These data indicate that the platinum (II) complexes may affect translational processes. (Figure 3 ) Similar effect was also observed with the more potent complex, Pt-IV ( Figure 4 ). The accumulation of cells in the G0/G1 phase was observed at 10-15 µM and at similar concentration (12.5-25 µM) a significant reduction of p53, PCNA and β-actin were observed. This observation prompted us to investigate the effect of these complexes on mRNA levels of p53. As expected, cisplatin significantly induced p53 mRNA by 3.9±1.3 fold ( Figure 5 ). Both Pt-VIII and Pt-XI showed a similar induction at the same concentration than cisplatin (100 µM), 2.7±1.0 and 3.1±0.1 fold, respectively. However, the most impressive induction of p53 mRNA (11.3±1.7 fold) was observed in response to 25 µM of Pt-IV. These data suggested that all the complexes induce p53 mRNA and that Pt-IV appears to be the more potent and more efficient on this cellular response. The induction of p53 indicate the nuclear DNA as a potential site of action of platinum (II) complexes. Thus, the cellular uptake was investigated by monitoring the platinum concentrations by ICP-MS from a total cell extract or DNA isolated from MDA-MB-231 incubated for 3 h with complexes and cisplatin as reference drug. Interestingly, all three platinum (II) complexes accumulate at much higher concentration into the cells compared to cisplatin, suggesting a more efficient cell membrane permeability ( Figure 6A ). The intracellular concentration of Pt-IV was 13.7-fold higher than cisplatin, although the amount of 195 Pt recovered from DNA samples of MDA-MB-231 cell lines exposed for 3 h to these complexes was significantly lower than cisplatin ( Figure 6B ). However, it must be considered that Pt-IV was utilized at four-fold lower concentration than cisplatin (25 µM vs 100 µM). Thus, it is tempting to speculate that the amount of Pt-IV that reached the DNA was proportionally higher than Pt-VIII and Pt-XI. 
Conclusions
In conclusion, the change in diamine ligand (8-aminequinoline vs 2-methyl-aminoimidazole) drastically modified the biological performance of the corresponding cationic platinum (II) complexes despite the same alkyl-imidazole moiety. These differences are evident not only in their accumulation in different cellular phase but also in the significant effect on mRNA levels of p53, on α-tubulin and on β-actin. In particular, these results suggest that Pt-IV is the most potent cytotoxic agent of this series of platinum (II) complexes and that it may act by interacting to the nuclear DNA as confirmed by accumulation data (ICP-MS). However, further analyses are required to better define its molecular mechanism of action.
Experimental Section
All manipulations involving air sensitive materials were carried out in an inert atmosphere glove box or using standard Schlenk line techniques, under an atmosphere of nitrogen or argon in oven-dried glassware. All solvents were used anhydrous. 1 H-NMR, 13 C-NMR and 195 Pt-NMR spectra were recorded on a Bruker DRX Avance 300 MHz equipped with a non-reverse probe (BBI) and also on a Bruker DRX Avance 600 MHz using as external reference K2PtCl4. MS analyses were performed by using a Thermo Finnigan (MA, USA) LCQ Advantage system MS spectrometer with an electrospray ionisation source and an 'Ion Trap' mass analyser. The MS spectra were obtained by direct infusion of a sample solution in MeOH under ionisation, ESI positive. Elemental analyses were performed using a Perkin Elmer SeriesII/CHNS/O 2400 Analyzer. Log Pow's values and purity were evaluated with Partisil C18-ODS reversed-phase HPLC column with Merck-Hitachi L-7100 equipped with Detector UV6000LP. ICP-MS data were recorded with BRUKER aurora M90 ICP-MS (MA, USA). Quinolin-8-amine (L1) is commercially available. (R)-and (S)-5,6,7,8-tetrahydroquinolin-8-amine (L3 and L4 respectively) were synthesized according to the procedure reported in literature. [11a, 16] Synthesis of (L2): To a solution of quinolin-8-amine (1 mmol, 144 mg) and NiCl2 6H2O (0.5 mmol, 138 mg) in methanol (10 mL), NaBH4 (4mmol, 151 mg) was added portion wise under cooling for 30 minutes, then the stirring was continued for other 30 minutes at room temperature. The solvent was removed in vacuo and the crude product was purified by flash chromatography (hexane/ethyl acetate 7:3) to afford L2 as a yellow oil. After dissolving the oil in acetone, HCl 4 M (2 equiv.) was added and upon layering diethyl ether the product was precipitated as a purple solid corresponding to the L2-dichloride salt. 12, 148.90, 141.99, 138.72, 130.72, 129.11, 128.23, 127.53, 123.74 ppm; 195 52, 141.75, 134.44, 128.23, 128.12, 123.26, 49.10, 24.49, 22.06 ppm; 195 01, 138.72, 136.57, 124.73, 61.45, 27.08, 26.90, 21.56 ppm; 195 3 General procedure for the synthesis of Pt-II, Pt-III, Pt-IV, Pt-VIII, Pt-IX, Pt-X and Pt-XI To a stirred solution in anhydrous DMF (1 mL) of the selected platinum dichloride complex (Pt-I, Pt-VI or Pt-VII, 1 mmol) the appropriate substituted N-alkyl imidazole (0.9 mmol) was added and the reaction mixture was warmed at 55 °C overnight under a nitrogen atmosphere. The solvent was then removed in vacuo and the oily residue was dissolved in dry methanol. After filtration of any eventually formed precipitate on a Celite pad, the solution was concentrated to give the crude product as an oil that upon washing with diethyl ether afforded the desired complex as a differently coloured powder. 49, 147.58, 140.39, 139.49, 139.15, 130.24, 129.23, 128.28, 127.73, 123.68, 123.30, 122.64, 34.22 ppm; 195 46, 148.10, 140.41, 139.48, 139.30, 130.08, 128.76, 127.79, 127.54, 123.28, 122.86, 120.59, 32.34, 19.17, 19.12, 12.42 ppm; 195 Pt NMR (300 MHz, CD3OD-d4) δ −2348 ppm; Elemental analysis of C16H20Cl2N4Pt: calcd. C, 35.96; H, 3.77; N, 10.49; found C, 36.37; H, 3.98; N, 10.44 44, 148.09, 140.38, 139.47, 130.21, 130.08, 129.21, 128.77, 128.51, 127.81, 127.54, 122.85, 49.23, 30.93, 29.74, 25.70, 22.13, 12.91 ppm; 195 Pt NMR (300 MHz, CD3OD-d4) δ −2324 ppm; Elemental analysis of C18H24Cl2N4Pt: calcd. C, 38.44; H, 4.30; N, 9.96; found C, 38.68; H, 4.79; N, 10.21; MS (ESI+) : m/z 526.95 [M] + 3. 3.4 ((R)-8-amino-5,6,7,8- 68, 146.17, 140.75, 137.16, 125.03, 124.33, 122.21, 121.30, 60.39, 48.27, 30.83, 30.20, 29.37, 26.41, 25.64, 22.09, 21.19, 12.86 ppm; 195 Pt NMR (300 MHz, CD3OD-d4) δ −2471 ppm; Elemental analysis of C18H28Cl2N4Pt: calcd. C, 38.17; H, 4.98; N, 9.89; found C, 38.56; H, 4.78; N, 9.95; MS (ESI+) : m/z 530.94 [M] + 3. 6, 7, 66, 151.12, 140.81, 138.56, 134.60, 127.83, 125.09, 116.09, 60.34, 47.86, 33,81, 29.39, 21.03; 195 Pt NMR (300 MHz, CD3OD-d4) δ −2412 ppm; Elemental analysis of C13H18Cl2N4Pt: calcd. C, 31.46; H, 3.66; N, 11.29; found C, 31.11; H, 3.97; N, 11.13 65, 146.23, 140.74, 139.94, 137.14, 128.44, 125.05, 122.19, 60.39, 47.87, 32.15, 29.37, 26.35, 21.07, 19.10, 12.37 ppm; 195 63, 146.22, 140.73, 137.13, 125.00, 124.31, 122.25, 121.31, 60.43, 48.23, 30.79, 30.23, 29.33, 26.45, 25.63, 22.13, 21.16, 12.83 ppm; 195 Pt NMR (300 MHz, CD3OD-d4) δ −2473 ppm; Elemental analysis of C18H28Cl2N4Pt: calcd. C, 38.17; H, 4.98; N, 9.89; found C, 38.53; H, 4.83; N, 9.91 Eagle's minimum essential medium (MEM) was purchased from Sigma Aldrich, while trypsin-EDTA, penicillin, streptomycin, sodium pyruvate, non-essential amino acid solution, fetal calf serum (FCS), plates and Petri dishes were purchased from EuroClone. The platinum(II) complexes were dissolved in dimethyl sulfoxide (DMSO) before performing each experiment. The maximal concentration utilized was 200 µM; cisplatin was tested up to 100 µM. The amount of DMSO did not exceed the 0.25% of the culture media volume. 3.5.2 Cell culture. Human triple negative cancer, MDA-MB-231, and ovarian carcinoma cell line, A2780, were cultured in DMEM supplemented with 10% FCS, non-essential amino acids, and penicillin/streptomycin at 37°C in a humidified atmosphere (5% CO2 and 95% air). 3.5.3 Cell viability assay. Sulphorhodamine B (SRB) assay was performed to assess the cell viability after treatments. 5x103 cells/well were seeded in a 96-well tray in triplicate. After 24h of incubation, the cells were treated with different concentrations of compounds. SRB assay were performed after 48h as previously described [17] . The determination of the conversion of MTT (3-(4,5-dimethyl-2thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide) to formazan was determined as previously described [18] . . RNA Preparation and Quantitative Real Time PCR-Total RNA was extracted with the iScriptTM RT-qPCR Sample Preparation Buffer (BIO-RAD) cDNA synthesis preparation reagents (Bio-Rad) according to manufacturer's instructions. Reverse transcription-polymerase first-strand cDNA synthesis was performed by using the Maxima First Strand cDNA Synthesis Kit (Thermo Scientific) [17] . qPCR was then performed by using the PowerUpTM SYBRTM Green Master Mix (Thermo Scientific) and specific primers for the selected genes. The primer sequences used for qPCR analysis were: p53 Forward 5'-GGAGGTTGTGAGGCGCTGG-3' Reverse 5'-CACGCACCTCAAAGCTGTTC-3'; 18S Forward 5'-CTCAACACGGGAAACCTCAC-3' Reverse 5'-CGCTCCACCAACTAAGAACG-3' [17] . The analyses were performed with the Mx3000P qPCR System (Agilent), with the following cycling conditions: 95°C, 2 min; 95°C, 15 sec and 60°C, 1 min for 40 cycles. Data were expressed as Ct values and used for
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